In sessions in the business of rheumatology track, rheumatology practice leaders will share ways to manage payer complexities head-on while also improving patient care.
1949 was a momentous year—astronomer Fred Hoyle coined the term Big Bang, the North Atlantic Treaty Organization (NATO) was formed, and Rodgers and Hammerstein’s classic musical South Pacific opened on Broadway.1 Much less recognized was the publication of an essay by Richard Asher, FRCP, titled the “Seven Sins of Medicine.”2 Although it’s over 75 years…
Kamini E. Kuchinad, MD, MPH, Ambereen Mehta, MD, MPH, David Wu, MD, & Jemima Albayda, MD |
“Our patients’ goals for their care aren’t always the same as ours. We’re typically focused on disease control, and they’re often focused on quality of life. Having ongoing discussions about care goals is the only way to know when it’s time to switch gears. Would you know when to refer your patients to palliative care?…
Improving reimbursement for underwater biosimilars is just one example of how the ACR’s practice advocates have achieved solutions to members’ insurance challenges. Here’s a look at current ACR efforts in insurance advocacy and how to get help with your own insurance challenges.
Revisions of the handbook to reflect an evolving healthcare landscape are underway, led by the Committee on Rheumatologic Care, Community Practice Council and Insurance Subcommittee. The first new chapters will be available in fall 2024.
Lucy Masto, BS, Medha Barbhaiya, MD, MPH, Caroline H. Siegel, MD, MS, Lisa R. Sammaritano, MD, & Michael D. Lockshin, MD |
Undifferentiated connective tissue disease (UCTD) is a diagnosis given to patients who do not fulfill current classification criteria for named connective tissue diseases (CTD)—systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or Sjögren’s disease—but who nonetheless have clinical signs and symptoms and serological evidence of autoimmune CTDs. In 1980 LeRoy et al. were…
In July, UHC announced it would discontinue reimbursement for G2211 for commercial plans as of Sept. 1. The ACR led a multispecialty sign-on letter urging the payer to reconsider its decision to help ensure clinicians can maintain the additional work needed to manage complex and chronic diseases.
It’s an election year, and ACR staff are excited about the possibility of moving key initiatives, such as Medicare reimbursement, across the finish line. But they need members’ help to do so.